These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 26916391)
1. JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus. Wenzel J; van Holt N; Maier J; Vonnahme M; Bieber T; Wolf D J Invest Dermatol; 2016 Jun; 136(6):1281-1283. PubMed ID: 26916391 [No Abstract] [Full Text] [Related]
2. Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency. Briand C; Frémond ML; Bessis D; Carbasse A; Rice GI; Bondet V; Duffy D; Chatenoud L; Blanche S; Crow YJ; Neven B Ann Rheum Dis; 2019 Mar; 78(3):431-433. PubMed ID: 30282666 [No Abstract] [Full Text] [Related]
3. JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus. Klaeschen AS; Wolf D; Brossart P; Bieber T; Wenzel J Exp Dermatol; 2017 Aug; 26(8):728-730. PubMed ID: 27892610 [TBL] [Abstract][Full Text] [Related]
4. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19. Goker Bagca B; Biray Avci C Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055 [TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib. Becker H; Engelhardt M; von Bubnoff N; Wäsch R Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798 [TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Vaddi K; Sarlis NJ; Gupta V Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187 [TBL] [Abstract][Full Text] [Related]
7. Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions. Fetter T; Smith P; Guel T; Braegelmann C; Bieber T; Wenzel J Front Immunol; 2020; 11():344. PubMed ID: 32194562 [TBL] [Abstract][Full Text] [Related]
8. Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib. Wei Q; Xu J Blood; 2024 Jul; 144(2):238. PubMed ID: 38990537 [No Abstract] [Full Text] [Related]
9. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. Ostojic A; Vrhovac R; Verstovsek S Future Oncol; 2011 Sep; 7(9):1035-43. PubMed ID: 21919691 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. Frémond ML; Rodero MP; Jeremiah N; Belot A; Jeziorski E; Duffy D; Bessis D; Cros G; Rice GI; Charbit B; Hulin A; Khoudour N; Caballero CM; Bodemer C; Fabre M; Berteloot L; Le Bourgeois M; Reix P; Walzer T; Moshous D; Blanche S; Fischer A; Bader-Meunier B; Rieux-Laucat F; Crow YJ; Neven B J Allergy Clin Immunol; 2016 Dec; 138(6):1752-1755. PubMed ID: 27554814 [No Abstract] [Full Text] [Related]